Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

An Alabama grandmother who was the first patient to receive a new kind of genetically modified pig kidney more than two months ago is now the longest surviving recipient of a pig organ.

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

The stock's fall snapped a five-day winning streak.

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases ...

You returns to Netflix this Spring, with Penn Badgley returning to our screen as Joe Goldberg in the fifth – and final – season of the series from Greg Berlanti and Sera Gamble. Will Joe ...

The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...